Remix Therapeutics promotes Dominic Reynolds to CSO post

1 February 2024

US clinical-stage biotech Remix Therapeutics today announced the appointment of Dominic Reynolds, as its chief scientific officer (CSO).

Dr Reynolds has been with Remix since its inception in 2019 and has been promoted from his previous role as senior vice president, head of drug discovery, where he led the design and synthesis of compounds to reformat RNA.

As part of this planned leadership transition, former CSO Zaven Kaprielian will join Remix’s scientific advisory board, where he will continue to advise on Remix’s evolving science and pipeline.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK